Combination Cancer Therapy Market by Cancer Type – Bladder cancer, Breast cancer, Colorectal cancer, Gastric cancer, Malignant melanoma, Multiple myeloma, Non-Hodgkin lymphoma (NHL), Non-Small-Cell Lung Cancer (NSCLC), Ovarian cancer, Prostate cancer, Renal Cell Carcinoma (RCC), Small-Cell Lung Cancer (SCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Forecast 2017-2025

Combination Cancer Therapy Market by Cancer Type – Bladder cancer, Breast cancer, Colorectal cancer, Gastric cancer, Malignant melanoma, Multiple myeloma, Non-Hodgkin lymphoma (NHL), Non-Small-Cell Lung Cancer (NSCLC), Ovarian cancer, Prostate cancer, Renal Cell Carcinoma (RCC), Small-Cell Lung Cancer (SCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Forecast 2017-2025

Combination cancer therapy combines two or more therapeutic agents to improve treatment response, minimize development of resistance or minimize adverse events. The amalgamation of anti-cancer drugs enhances efficacy compared to the mono-therapy approach because it targets key pathways in a characteristically synergistic or an additive manner. This approach potentially reduces drug resistance, while simultaneously providing therapeutic anti-cancer benefits, such as reducing tumor growth and metastatic potential, arresting mitotically active cells, reducing cancer stem cell populations, and inducing apoptosis. Therefore, new treatment combinations and strategies that target the survival pathways that provide efficient and effective results at an affordable cost are being considered. For example, combination regime of the two HER2 (ERBB2)-targeted drugs, pertuzumab (Perjeta) and trastuzumab (Herceptin), together with the chemotherapeutic agent docetaxel achieved higher overall survival rate in metastatic breast cancer patients over other therapies. Similarly, chemotherapy drugs are most effective when given in combination, and when drugs with different effects are combined, each drug can be used at its optimal dose, without intolerable side effects. Combination chemotherapy can be useful for people with advanced cancers that are not suitable for radiation therapy or surgical treatment.

The global combination cancer therapy market segmentation is based on cancer type – bladder cancer, breast cancer, colorectal cancer, gastric cancer, malignant melanoma, multiple myeloma, non-hodgkin lymphoma (NHL), Non-small-cell lung cancer (NSCLC), ovarian cancer, prostate cancer, renal cell carcinoma (RCC), small-cell lung cancer (SCLC), and squamous cell carcinoma of the head and neck (SCCHN).

The global combination cancer therapy market research report provides market size (Revenue US$ Million 2014 to 2025), market share analysis, growth trends and forecast (CAGR%, 2017 to 2025). The global combination cancer therapy market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global combination cancer therapy market report provides detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global combination cancer therapy market and profiled in this report include Amgen, Aragon Pharmaceuticals, Argos Therapeutics, Array BioPharma, AstraZeneca, Bristol-Myers Squibb, Celgene, Exelixis, GlaxoSmithKline, Merck & Co., Millennium Pharmaceuticals, Novartis, Pfizer, Roche Holding AG, Takeda Pharmaceutical Company, and VBL Therapeutics.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Combination Cancer Therapy Market

1. Cancer Type
1.1. Bladder cancer
1.2. Breast cancer
1.3. Colorectal cancer
1.4. Gastric cancer
1.5. Malignant melanoma
1.6. Multiple myeloma
1.7. Non-Hodgkin lymphoma (NHL)
1.8. Non-Small-Cell Lung Cancer (NSCLC)
1.9. Ovarian cancer
1.10. Prostate cancer
1.11. Renal Cell Carcinoma (RCC)
1.12. Small-Cell Lung Cancer (SCLC)
1.13. Squamous Cell Carcinoma of the Head and Neck (SCCHN)

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. Amgen
3.2. Aragon Pharmaceuticals
3.3. Argos Therapeutics
3.4. Array BioPharma
3.5. AstraZeneca
3.6. Bristol-Myers Squibb
3.7. Celgene
3.8. Exelixis
3.9. GlaxoSmithKline
3.10. Merck & Co.
3.11. Millennium Pharmaceuticals
3.12. Novartis
3.13. Pfizer
3.14. Roche Holding AG
3.15. Takeda Pharmaceutical Company
3.16. VBL Therapeutics

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*